Clin Endosc.  2017 Jan;50(1):1-2. 10.5946/ce.2017.014.

Endoscopic Findings of Gastric Extranodal Marginal Zone B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma

• Lee SK

• KMID: 2383480
• DOI: http://doi.org/10.5946/ce.2017.014

Abstract

No abstract available.

MeSH Terms

B-Lymphocytes*
Lymphoma, B-Cell, Marginal Zone*

Reference

1. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi144–vi148.

2. Bertoni F, Coiffier B, Salles G, et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park). 2011; 25:1134–1142. 1147.

3. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012; 33:297–305.

4. Ferreira M, Domingues RG, Veiga-Fernandes H. Stroma cell priming in enteric lymphoid organ morphogenesis. Front Immunol. 2012; 3:219.

5. Taal BG, den Hartog Jager FC, Tytgat GN. The endoscopic spectrum of primary non-Hodgkin’s lymphoma of the stomach. Endoscopy. 1987; 19:190–192.

6. Kolve M, Fischbach W, Greiner A, Wilms K. Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin’s lymphoma. German gastrointestinal lymphoma study group. Gastrointest Endosc. 1999; 49(3 Pt 1):307–315.

7. Yokoi T, Nakamura T, Kasugai K, et al. Primary low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma with polypoid appearance. Polypoid gastric MALT lymphoma: a clinicopathologic study of eight cases. Pathol Int. 1999; 49:702–709.

8. Li X, Wang X, Zhan Z, Zhang L, Sun B, Zhang Y. Evaluation of the clinical characteristics, management, and prognosis of 103 patients with gastric mucosa-associated lymphoid tissue lymphoma. Oncol Lett. 2016; 11:1713–1718.

9. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001; 357:39–40.

10. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992; 102:1628–1638.

11. Lee CM, Lee DH, Ahn BK, et al. Correlation of endoscopic findings of gastric mucosa-associated lymphoid tissue lymphoma with recurrence after complete remission. Clin Endosc. 2017; 50:51–57.

12. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001; 48:297–303.

13. Park S, Ahn S, Hong M, Ko YH. Increased plasmacytic differentiation in gastric mucosa-associated lymphoid tissue lymphomas: Helicobacter pylori eradication response and IgG4+ plasma cell association. Hum Pathol. 2017; 59:113–119.

14. Malikhova OA, Poddubnyĭ BK, Poddubnaia IV, Moskalenko OA, Kontsevaia A. [Endoscopic criteria for diagnosis of various macroscopic variants of non-Hodgkin’s gastric lymphoma]. Eksp Klin Gastroenterol. 2010; (9):33–37.

15. Nonaka K, Ohata K, Matsuhashi N, et al. Is narrow-band imaging useful for histological evaluation of gastric mucosa-associated lymphoid tissue lymphoma after treatment? Dig Endosc. 2014; 26:358–364.